
CLIA Kit for Fibroblast Growth Factor 21 (FGF21)
- Product No.CCC918Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- All
- Human
- Mouse
- Rat
- Cavia
- Rabbit
- Simian
- Caprine
- Ovine
- Equine
- Bovine
- Porcine
- Gallus
- Canine
- Others
- Multi-species
- Pan-species
- Test MethodCompetitive Inhibition
- Assay Length2h
- Detection Range1.17-300pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.43pg/mL.
- Sample TypeSerum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- DownloadInstruction Manual
- UOM48T96T96T*596T*1096T*100
- FOBUS$ 638 For more details, please contact local distributors!US$ 912 For more details, please contact local distributors!US$ 4104 For more details, please contact local distributors!US$ 7752 For more details, please contact local distributors!US$ 63840 For more details, please contact local distributors!
Specificity of the CLIA Kit for Fibroblast Growth Factor 21 (FGF21)
This assay has high sensitivity and excellent specificity for detection of Fibroblast Growth Factor 21 (FGF21).No significant cross-reactivity or interference between Fibroblast Growth Factor 21 (FGF21) and analogues was observed.
Recovery of the CLIA Kit for Fibroblast Growth Factor 21 (FGF21)
Matrices listed below were spiked with certain level of recombinant Fibroblast Growth Factor 21 (FGF21) and the recovery rates were calculated by comparing the measured value to the expected amount of Fibroblast Growth Factor 21 (FGF21) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 99-105 | 102 |
EDTA plasma(n=5) | 95-104 | 101 |
heparin plasma(n=5) | 91-98 | 94 |
Precision of the CLIA Kit for Fibroblast Growth Factor 21 (FGF21)
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Fibroblast Growth Factor 21 (FGF21) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Fibroblast Growth Factor 21 (FGF21) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CV<10%>10%>Inter-Assay: CV<12%>12%>
Linearity of the CLIA Kit for Fibroblast Growth Factor 21 (FGF21)
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Fibroblast Growth Factor 21 (FGF21) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 94-102% | 79-94% | 78-95% | 80-88% |
EDTA plasma(n=5) | 89-101% | 80-102% | 78-104% | 79-99% |
heparin plasma(n=5) | 97-105% | 98-105% | 79-89% | 83-105% |
Stability of the CLIA Kit for Fibroblast Growth Factor 21 (FGF21)
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Assay procedure summary of the CLIA Kit for Fibroblast Growth Factor 21 (FGF21)
1. Prepare all reagents, samples and standards;2. Add 50µL standard or sample to each well.And then add 50µL prepared Detection Reagent A immediately. Shake and mix. Incubate 1 hour at 37°C;3. Aspirate and wash 3 times;4. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;5. Aspirate and wash 5 times;6. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;7. Read RLU value immediately.
Test principle of the CLIA Kit for Fibroblast Growth Factor 21 (FGF21)
The microplate provided in this kit has been pre-coated with a monoclonal antibody specific to Fibroblast Growth Factor 21 (FGF21). A competitive inhibition reaction is launched between biotin labeled Fibroblast Growth Factor 21 (FGF21) and unlabeled Fibroblast Growth Factor 21 (FGF21) (Standards or samples) with the pre-coated antibody specific to Fibroblast Growth Factor 21 (FGF21). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Fibroblast Growth Factor 21 (FGF21) in the sample. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is reverse proportional to the Fibroblast Growth Factor 21 (FGF21) level in the sample or standard.
GIVEAWAYS
ELISA / CLIA Experiment Service
INCREMENT SERVICES
Single-component Reagents of Assay KitLysis Buffer Specific for ELISA / CLIAQuality Control of ELISA / CLIACLIA Kit Customized ServiceDisease Model Customized ServiceSerums Customized ServiceTGFB1 Activation ReagentReal Time PCR Experimental Service
Related products
Catalog No. | Organism species: Rattus norvegicus (Rat) | Applications (RESEARCH USE ONLY!) |
APC918Ra01 | Active Fibroblast Growth Factor 21 (FGF21) | Cell culture; Activity Assays. |
RPC918Ra02 | Recombinant Fibroblast Growth Factor 21 (FGF21) | Positive Control; Immunogen; SDS-PAGE; WB. |
EPC918Ra61 | Eukaryotic Fibroblast Growth Factor 21 (FGF21) | Positive Control; Immunogen; SDS-PAGE; WB. |
RPC918Ra01 | Recombinant Fibroblast Growth Factor 21 (FGF21) | Positive Control; Immunogen; SDS-PAGE; WB. |
PAC918Ra02 | Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) | WB; IHC; ICC; IP. |
PAC918Ra01 | Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) | WB; IHC; ICC; IP. |
MAC918Ra21 | Monoclonal Antibody to Fibroblast Growth Factor 21 (FGF21) | WB; IHC; ICC; IP. |
SEC918Ra | ELISA Kit for Fibroblast Growth Factor 21 (FGF21) | Enzyme-linked immunosorbent assay for Antigen Detection. |
CEC918Ra | ELISA Kit for Fibroblast Growth Factor 21 (FGF21) | Enzyme-linked immunosorbent assay for Antigen Detection. |
WEC918Ra | Wide-range ELISA Kit for Fibroblast Growth Factor 21 (FGF21) | Enzyme-linked immunosorbent assay for Antigen Detection. |
CCC918Ra | CLIA Kit for Fibroblast Growth Factor 21 (FGF21) | Chemiluminescent immunoassay for Antigen Detection. |
PGC918Ra01 | Primer Pair for Fibroblast Growth Factor 21 (FGF21) | PCR |
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
谁的答案详细、真实分就给谁...(勿灌水,否则必究之)
想做临床的血标本的一些代谢组学研究,不知道应该用血浆还是血清,大家的说法好像也不太一致,请大神指导啊,最好有些参考文献,谢谢!
当抗体结合到示踪剂上时,340nm的激发光激发铕标分子,导致能量转移到Alexa Fluor 647染料上,结果产生665nm的发射光。荧光的强度与样品中的cAMP含量成反比。
本试剂盒用于检测在GPCR激动剂刺激下活细胞或者细胞膜制备品产生的cAMP。对于偶联Gαs的受体,激动剂刺激导致665nm的荧光强度降低,而拮抗剂则可以逆转这一效应;对于偶联Gαi的受体,在激动剂刺激的同时用forskolin刺激cAMP产生,那么激动剂则抑制forskolin诱导的cAMP的生成,因此对照只给forskolin的细胞组可以通过665nm荧光强度的增加反应激动剂的效应。
该试剂盒的灵敏度很高,室温下反应在20h内是稳定的。本试剂盒适用于在384孔板中进行24μl的微量分析。
2.保存条件
避光2~4℃保存,过期时间见装。
3.盒内试剂
cAMP标准品:1管,1ml。(50μM)
生物素标记的cAMP(b-cAMP):1管,25μl。
铕标的抗生物素蛋白链菌素:1管,25μl。
荧光标记的cAMP抗体:1管,40μl。
检测缓冲液:1瓶,25ml。
4.需要自配的其他溶液
l Hank’s balanced salt solution (HBSS): NaCl 8.0g、CaCl2 0.14g、KCl 0.4g、 KH2PO4 0.06g、Na2HPO4?7H2O0.09g、MgCl2.6H2O0.10 g、MgSO4.7H2O0.10 g、NaHCO30.35g、葡萄糖1.0g,加H2O至 1000ml (用7.5%NaHCO调节PH值=7.4)
l Versene消化液(1L):EDTA 0.372 g,NaCl 8.0g,KCl 0.20 g,KH2PO40.20g,Na2HPO4 1.15 g,D-glucouse 0.2 g,pH 7.4
l HEPES缓冲液(1mol/L):取2.383gHEPES溶于10ml去离子水中。
l 7.5%BSA溶液:取0.75gBSA溶于10ml去离子水中
l 0.5M IBMX溶液:11.11mg IBMX溶于100μl DMSO中,-20℃冻存。
l 刺激缓冲液(SB):14 ml HBSS(1×)+75μlHEPES(1mol/L)+200μlBSA (7.5%)。(注:在测定细胞cAMP时,反应缓冲液中要加入IBMX 0.5mmol/L)
l 吗啡贮存液(10mM):盐酸吗啡37.585mg溶于10ml生理盐水中,0.22μm滤膜过滤除菌,4℃保存备用。
l 纳络酮母液(100mM):纳络酮4mg溶于100μl 生理盐水中,用时工作液按照1:500稀释,溶剂为含有IBMX的反应缓冲液。
认领翻译的战友请跟帖注明“认领本文翻译,48小时内未完成,请其他站友认领”
MaggotsFasterThanScalpelinWoundDebridement
December19,2011—Maggotdebridementtherapy(MDT)appearstobemoreeffectiveforwounddebridementcomparedwithconventionaltherapy,butonlyat1week;afterthattime,anothertypeofdressingshouldbeused,newresearchsuggests.
KristinaOpletalovà,MD,fromtheDepartmentofDermatology,UniversityofCaen,France,andcolleaguespublishedonlineDecember19intheArchivesofDermatology.
MedicalmaggotswereapprovedbytheUSFoodandDrugAdmiNISTrationasamedicaldeviceforwounddebridementin2004.Accordingtotheresearchers,useofmaggotsintreatingwoundsisassociatedwitheffectivewounddebridement,antibacterialeffects,andstimulationofwoundhealing.
However,theypointout,"[r]elativelyfewclinicalstudieshavebeenconductedandtheresultsarenotclear,partlyowingtomethodologicassessmentproblems."
InthecurrentProspective,randomizedcontrolled,phase3clinicaltrial,theresearcherssoughttodeterminetheefficacyofbaggedlarvaeonwounddebridementincomparisonwithconventionaltreatment.
TheprimaryobjectivewastocomparethemeanpercentageofsloughinwoundstreatedwithMDTwiththatofconventionaltreatmentatday15.Thestudyincluded119patientswithanonhealing,sloughywoundthatwas40cm2orsmallerandlessthan2cmdeep.Patientsalsohadananklebrachialindexof0.8orhigher.
Treatmentwasadministeredduringa2-weekhospitalstay.Conventionaltreatmentconsistedofsurgicaldebridement3timesaweekwithascalpel,withuseoftopicalanesthesia.TheMDTwasadministeredusinganencloseddressing(Vitapad,BioMondeLaboratories)containing80sterilemaggots.Atdischarge,aconventionaldressingwasapplied,andpatientswerefollowed-upatday30.
DebridementbyMDTwassignificantlyfasterthansurgicaldebridementduringthefirstweekoftreatment,reachingthesamelevelthecontrolgroupreachedatday15.NobenefitforMDTcomparedwithconventionaltreatmentinhealingrateswasobserved.Atday8,54.5%intheMDTgroupvs66.5%inthecontrolgroup(P=.04)hadevidenceofsloughandwoundhealing.However,byday15,themeanpercentageofsloughwas55.4%intheMDTgroupand53.8%inthecontrolgroup(P=.78).
"AthoughMDTshowsnosignificantbenefitatday15comparedwithconventionaltreatment,debridementbyMDTissignificantlyfasterandoccursduringthefirstweekoftreatment,"theresearchersconclude."Becausethereisnobenefitincontinuingthetreatmentafter1week,anothertypeofdressingshouldbeusedafter2or3applicationsofMDT."
Painscoresweresimilarandmildinbothgroups,althoughincontrasttoconventionaltreatment,MDTwasperformedwithouttopicalanesthesia.
Accordingtotheresearchers,noneofthepatientswerereticentaboutundergoingMDT."[A]crawlingsensationonthewoundwasrarelyandalmostequallynotedinbothgroups,revealingthatthesensationwassubjective,"Dr.Opletalovàandcolleaguespointout.
TwoquestionsregardingMDTremainunanswered,theauthorsnote."Candebridementbeimprovedusingmoremaggotsperdressing?Ifso,wouldthesedressingsbemorepainful?Furtherstudiesareneededtoanswerthesequestions."
ThestudywassupportedbygrantsfromtheClinicalResearchHospitalProgramandfromtheFrenchSocietyofDermatology.Theauthorshavedisclosednorelevantfinancialrelationships.
一、细胞冷冻保存
1.材料:
生长良好之培养细胞、新鲜培养基、DMSO(SigmaD-2650)、无菌塑料冷冻保存管(Nalgene 5000-0020)、0.4%(w/v)trypanblue(GibcoBRL15250-061)、血球计数盘与盖玻片、等速降温机(KRYO10SeriesII)
2、冷冻保存方法:
(1)传统方法:冷存管置于4℃10分钟--->-20℃30分钟--->-80℃16~18小时(或隔夜)--->液氮槽vaporphase长期储存。
-20℃不可超过1小时,以防止胞内冰晶过大,造成细胞大量死亡,亦可跳过此步骤直接放入-80℃冰箱中,惟存活率稍微降低一些。
(2)程序降温:利用已设定程序的等速降温机以-1~-3℃/分钟之速度由室温降至(-80℃以下)-120℃,再放在液氮槽vaporphase长期储存。适用于悬浮型细胞与hybridoma之保存。
3、步骤:
(1)冷冻前24-48小时更换半量或全量培养基,使细胞处于指数生长期。
(2)配制冷冻保存溶液(使用前配制):另取一离心管,加入培养基、血清,逐滴加入二甲基亚砜(DMSO)至20%浓度,即制成双倍的冻存液,置于室温下待用。
(3)离心收集培养之细胞,用加血清的培养基重悬起细胞,取少量细胞悬浮液(约0.1ml)计数细胞浓度及冻前存活率。
(4)取与细胞悬液等量的冻存液,缓慢逐滴加入细胞悬液,并晃动试管,制成细胞冻存悬液(DMSO最后浓度为5~10%),使细胞浓度为1~5×106cells/ml,混合均匀,分装于已标示完全之冷冻保存管中,1~2ml/vial,并取少量细胞悬浮液作污染检测。严密封口后,注明细胞名称、代数、日期。然后进行冻存。
4、注意事项:
(1)欲冷冻保存之细胞应在生长良好(logphase)且存活率高之状态,约为80~90%致密度。冷冻前检测细胞是否仍保有其特有性质,例如hybridoma应在冷冻保存前一至二日测试是否有抗体之产生。
(2)细胞在液氮中可长期冻存无限时间,而不会影响细胞活力;在-70度可保存数月。
(3)注意冷冻保护剂之品质。DMSO应为试剂级等级,无菌且无色(以0.22micron FGLP Telflon过滤或是直接购买无菌产品,如SigmaD-2650),以5~10ml小体积分装,4℃避光保存,勿作多次解冻。Glycerol亦应为试剂级等级,以高压蒸汽灭菌后避光保存。在开启后一年内使用,因长期储存后对细胞会有毒性。本方法中先制备双倍冻存液,可避免DMSO直接加入时释放的热量对细胞的损伤。缓慢逐滴加入细胞悬液是使细胞逐步适应高渗,可降低细胞受损。DMSO可能引起部分白血病细胞株的分化,可换用10%甘油冻存。
(4)冷冻保存之细胞浓度:
①normalhumanfibroblast:1~3×106cells/ml
②hybridoma:1~3×106cells/ml,细胞浓度不要太高,某些hybridoma会因冷冻浓度太高而在解冻24小时后死去。
③adherenttumorlines:5~7×106,依细胞种类而异。Adenocarcinoma解冻后须较高之浓度,而HeLa只需1~3×106cells/ml
④othersUSPensions:5~10×106cells/ml,humanlymphocyte须至少5×106cells/ml。
(5)冷冻保护剂浓度为5或10%DMSO,若是不确定细胞之冷冻条件,在做冷冻保存之同时,亦应作一个backupculture,以防止冷冻失败。
(6)冻存可用10%~90%的血清,一般高浓度血清有助于维护细胞活力,此处介绍20%终浓度有利于细胞悬浮而少沉积(4度时),复苏存活率在80%~90%以上,对原代培养细胞,以90%血清冻存更为有效。
二、冷冻细胞活化
1、冷冻细胞之活化原则为快速解冻,以避免冰晶重新结晶而对细胞造成伤害,导致细胞之死亡。
2、细胞活化后,约需数日,或继代一至二代,其细胞生长或特性表现才会恢复正常(例如产生单株抗体或是其它蛋白质)。
3、材料
37℃恒温水槽、新鲜培养基、无菌吸管/离心管/培养瓶、液氮或干冰容器
4、步骤:
(1)操作人员应戴防护面罩及手套,防止冷冻管可能爆裂之伤害。
(2)自液氮或干冰容器中取出冷冻管,检查盖子是否旋紧,由于热胀冷缩过程,此时盖子易松掉。
(3)将新鲜培养基置于37℃水槽中回温,回温后喷以70%酒精并擦拭之,移入无菌操作台内。
(4)取出冷冻管,立即放入37℃水槽中快速解冻,轻摇冷冻管使其在1分钟内全部融化,以70%酒精擦拭保存管外部,移入无菌操作台内。
(5)取出解冻之细胞悬浮液,缓缓加入有培养基之培养容器内(稀释比例为1:10~1:15),混合均匀,放入CO2培养箱培养。取0.1ml解冻细胞悬浮液作存活测试。
(6)解冻后是否立即去除冷冻保护剂(例如DMSO或glycerol),依细胞种类而异,一般而言,大都不需要立即去除冷冻保护剂。惟若要立即去除,则将解冻之细胞悬浮液加入含有5-10ml培养基之离心管内,离心1000rpm,5分钟,移去上清液,加入新鲜培养基,混合均匀,放入CO2培养箱培养。
(7)若不需立即去除冷冻保存剂,则在解冻培养后隔日更换培养基。
三、细胞计数与存活测试
1、原理:
(1)计算细胞数目可用血球计数盘或是Coultercounter粒子计数器自动计数。
(2)血球计数盘一般有二个chambers,每个chamber中细刻9个1mm2大正方形,其中4个角落之正方形再细刻16个小格,深度均为0.1mm。当chamber上方盖上盖玻片后,每个大正方形之体积为1mm2×0.1mm=1.0x10-4ml。使用时,计数每个大正方形内之细胞数目,乘以稀释倍数,再乘以104,即为每ml中之细胞数目。
(3)存活测试之步骤为dyeexclusion,利用染料会渗入死细胞中而呈色,而活细胞因细胞膜完整,染料无法渗入而不会呈色。一般使用蓝色之trypanblue染料,如果细胞不易吸收trypanblue,则用红色之Erythrosinbluish。计算细胞活率:活细胞数/(活细胞数+死细胞数)×100%。计数应在台盼兰染色后数分钟内完成,随时间延长,部分活细胞也开始摄取染料;因为台盼兰对蛋白质有很强的亲和力,用不含血清的稀释液,可以使染色计数更为准确。
2、材料:
0.4%w/vtrypanblue(GibcoBRL15250-061);Erythosinbluishstain;取0.1gramErythrosinbluish(SigmaE-9259)及0.05grampreservativemethylparaben(SigmaH-3647)溶于100mlCa++/Mg++freesaline;血球计数盘及盖玻片(Hemocytometerandcoverslip);计数器(counter);低倍倒立显微镜;粒子计数器(Coultercounter,CoulterElectronics)。白细胞稀释液(4%乙酸溶液)。
3、步骤:
(1)取50μl细胞悬浮液与50μltrypanblue(orErythrosinbluish)等体积混合均匀于1.5ml小离心管中。
(2)取少许混合液(约15μl)自血球计数盘chamber上方凹槽加入,盖上盖玻片,于100倍倒立显微镜下观察,活细胞不染色,死细胞则为蓝色(或红色-Erythrosinbluish)。
(3)计数四个大方格之细胞总数,再除4,乘以稀释倍数(至少乘以2,因与trypanblue等体积混合),最后乘以104,即为每ml中细胞悬浮液之细胞数。若细胞位于线上,只计上线与右线之细胞(或计下线与左线之细胞)。
注:4大格细胞总数×稀释倍数×104/4=细胞数/ml;每一大格的体积=0.1cm×0.1cm×0.01cm=10-4ml
计数板计数时,最适浓度为5~10×105细胞/ml,此范围外计数误差偏大。高浓度细胞悬液,可取出部分作稀释或连续稀释后计数。
5、范例:
T75monolayerculture制成10ml细胞悬浮液,取0.1ml溶液与0.1mltrypanblue混合均匀于试管中,取少许混合液加入血球计数盘,计数四大方格内之细胞数目。
活细胞数/方格:55,62,49,59;死细胞数/方格:5,3,4,6;细胞总数=243
平均细胞数/方格=60.75;稀释倍数=2;
细胞数/ml:60.75×104×2(稀释倍数)=1.22×106;
细胞数/flask(10ml):1.22×106×10ml=12.2×106
存活率:225/243﹦92.6%

